These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21443465)

  • 1. Targeting FoxO1 for hypertriglyceridemia.
    Kim DH; Zhang T; Ringquist S; Dong HH
    Curr Drug Targets; 2011 Aug; 12(9):1245-55. PubMed ID: 21443465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FoxO1 integrates insulin signaling to VLDL production.
    Kamagate A; Dong HH
    Cell Cycle; 2008 Oct; 7(20):3162-70. PubMed ID: 18927507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice.
    Kamagate A; Qu S; Perdomo G; Su D; Kim DH; Slusher S; Meseck M; Dong HH
    J Clin Invest; 2008 Jun; 118(6):2347-64. PubMed ID: 18497885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.
    Kim DH; Zhang T; Lee S; Calabuig-Navarro V; Yamauchi J; Piccirillo A; Fan Y; Uppala R; Goetzman E; Dong HH
    Endocrinology; 2014 Apr; 155(4):1255-67. PubMed ID: 24437489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.
    Altomonte J; Cong L; Harbaran S; Richter A; Xu J; Meseck M; Dong HH
    J Clin Invest; 2004 Nov; 114(10):1493-503. PubMed ID: 15546000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.
    Qu S; Su D; Altomonte J; Kamagate A; He J; Perdomo G; Tse T; Jiang Y; Dong HH
    Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E421-34. PubMed ID: 16985262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FoxO1 and hepatic lipid metabolism.
    Sparks JD; Dong HH
    Curr Opin Lipidol; 2009 Jun; 20(3):217-226. PubMed ID: 21037971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overindulgence and metabolic syndrome: is FoxO1 a missing link?
    Sparks JD; Sparks CE
    J Clin Invest; 2008 Jun; 118(6):2012-5. PubMed ID: 18497882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice.
    Tanaka H; Nagashima T; Shimaya A; Urano Y; Shimokawa T; Shibasaki M
    Eur J Pharmacol; 2010 Oct; 645(1-3):185-91. PubMed ID: 20655898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic insulin expression on lipid metabolism in diabetic mice.
    Qu S; Zhang T; Dong HH
    J Diabetes; 2016 May; 8(3):314-23. PubMed ID: 25851734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.
    Dash S; Xiao C; Morgantini C; Szeto L; Lewis GF
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2895-901. PubMed ID: 24072699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia.
    Sparks JD; Sparks CE; Adeli K
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2104-12. PubMed ID: 22796579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia.
    Haeusler RA; Han S; Accili D
    J Biol Chem; 2010 Aug; 285(35):26861-26868. PubMed ID: 20573950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
    Mangaloglu L; Cheung RC; Van Iderstine SC; Taghibiglou C; Pontrelli L; Adeli K
    Metabolism; 2002 Apr; 51(4):409-18. PubMed ID: 11912545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridemia secondary to obesity and diabetes.
    Subramanian S; Chait A
    Biochim Biophys Acta; 2012 May; 1821(5):819-25. PubMed ID: 22005032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired-inactivation of FoxO1 contributes to glucose-mediated increases in serum very low-density lipoprotein.
    Wu K; Cappel D; Martinez M; Stafford JM
    Endocrinology; 2010 Aug; 151(8):3566-76. PubMed ID: 20501667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.
    Qu S; Altomonte J; Perdomo G; He J; Fan Y; Kamagate A; Meseck M; Dong HH
    Endocrinology; 2006 Dec; 147(12):5641-52. PubMed ID: 16997836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression.
    Zhu X; Wu YB; Zhou J; Kang DM
    Biochem Biophys Res Commun; 2016 Jan; 469(2):319-25. PubMed ID: 26603935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans.
    Sajan MP; Ivey RA; Farese RV
    Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance.
    Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV
    Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.